Previous 10 | Next 10 |
Orchard Therapeutics ( ORTX ) was founded in 2015 and has been dedicated to advancing gene therapies for ultra-rare diseases. In 2018, they acquired GSK’s portfolio of gene therapies and became a public company. Orchard now has one of the most extensive and advanced pipelines in the g...
The FDA designates Orchard Therapeutics' ( ORTX -2.2% ) OTL-203, an ex vivo autologous hematopoietic stem cell gene therapy, an Orphan drug and rare pediatric disease, for mucopolysaccharidosis type I (MPS-I), a rare neurometabolic disease caused by a deficiency of the a...
BOSTON and LONDON, July 20, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company has received both orphan drug designation and rare pediatric disease designation from the U.S Food and Drug Administration (FDA) for OTL-2...
Orchard Therapeutics (NASDAQ: ORTX ) jumps 9% premarket after entering into two worldwide royalty-bearing license agreements with GlaxoSmithKline (NYSE: GSK ) for use of its lentiviral stable cell line technology (LV-SCLT) for Orchard’s investigational hema...
BOSTON and LONDON, July 15, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company has entered into two worldwide royalty-bearing license agreements with GlaxoSmithKline plc (GSK) (LSE/NYSE: GSK) for use of their propriet...
BOSTON and LONDON and MILAN, Italy, July 09, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, and MolMed S.p.A (MLMD.MI), one of the company’s principal contract development and manufacturing partners, today announced that they have extended...
The following slide deck was published by Orchard Therapeutics plc in conjunction with this Read more ...
BOSTON and LONDON, May 27, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that presentations by the management team will be made at the following investor conferences in June: Jefferies Virtual Global Healthcare Conference on ...
First Primary Outcome Measure Met with All Eight Patients Achieving Hematologic Engraftment Improved Motor Skills, Stable Cognitive Scores and Normal Growth Seen in First Two Patients One-year Follow-up Results and Initiation of Registrational Trial Expected in 2021 BOSTON and...
Orchard Therapeutics ( ORTX ) is an undercovered, $1.7bn London-headquartered company positioning itself to be the market leader in next-generation, cryopreserved, easily accessible, lentiviral vector based gene therapy. The company originally had 2 gene therapy assets. In 2018, Orchard Therap...
News, Short Squeeze, Breakout and More Instantly...
Orchard Therapeutics plc Company Name:
ORTX Stock Symbol:
NASDAQ Market:
Orchard Therapeutics plc Website:
TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced that Bobby Gaspar, M.D., Ph.D., co-founder and chief executive officer, ...
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...
Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient’s own hematopoietic stem cells HURCULES study to enroll 40 patients at clinical sites across the U.S....